Você procurou por: substance use disorder (Inglês - Maltês)

reducing substance use disorders
it-tnaqqis ta’ disturbi minn użu ta’ sustanzi

patients with substance use/abuse
tkabbir u żvilupp (tfal u adolexxenti)

patients with substance use/abuse:
pazjenti li jużaw/jabbużaw sustanzi (drogi):

relatively little is known about the treatment of substance use in older adults.
ftit li xejn għandna tagħrif fuq il-kura ta’ l-użu ta’ sustanzi mill-anzjani.

early onset users typically have a long history of substance use which persists into old age.
min beda jużahom kmieni ġeneralment ikollu storja twila ta’ użu tassustanzi li tkompli sax-xjuħija.

early intervention for re-emergence or development of psychiatric disorders and substance use is recommended.
huwa rakkomandat intervent bikri għad-dehra mill-ġdid jew l-iżvilupp ta’ disturbi psikjatriċi u użu ta’ sustanzi.

about 30–50 % of psychiatric patients in europe today have a mental illness as well as a substance use disorder, mainly with alcohol, sedatives or cannabis.
madwar 30–50% tal-pazjenti psikjatriċi fl-ewropa fil-preżent għandhom marda mentali kif ukoll problema ta’ użu ta’sustanzi, l-iktar l-alkoħol, il-kalmanti jew il-kannabis.

many of these are risk factors for substance misuse among older persons, and may in turn be aggravated by substance use.
problemi bħal dawn jistgħu jinteraġixxu ma’ proċessi oħra biex jaċċelleraw il-progressjoni, jew iżidu l-gravità ta’ indebolimenti newrokonoxxittivi assoċjati max-xjuħija.

improved assessment of substance use disorders among older adults may therefore require age-specific measures of use and dependence.
valutazzjoni aħjar tad-disturbi kkaġunati mill-użu ta’ sustanzi fost persuni adulti kbar fletà tista’ għalhekk teħtieġ miżuri ta’ użu u dipendenza speċifiċi għalletà.

also, a clearer distinction may be required between different types of substance use to take into account a range of behavioural and clinical manifestations.
barra dan, tista’ tkun meħtieġa distinzjoni aktar ċara bejn tipi differenti ta’ użu tassustanzi sabiex titqies firxa ta’ manifestazzjonijiet komportamentali u kliniċi.

however, despite their regular contact with healthcare professionals, substance use disorders among older persons are often missed or misdiagnosed.
madankollu, minkejja l-kuntatt regolari tagħhom mal-professjonisti tal-kura tassaħħa, id-disturbi kkaġunati mill-użu tassustanzi fost persuni akbar fletà ħafna drabi ma jiġux magħrufin jew ikunu suġġetti għal dijanjożi żbaljata.

however, forecasts for the coming years are troubling and substance use by older adults is likely to become a neglected problem among our neglected citizens.
madankollu, il-previżjonijiet għas-snin li ġejjin huma inkwetanti, u l-użu ta’ sustanzi minn persuni adulti kbar fletà aktarx isir problema injorata fost iċ-ċittadini injorati tagħna.

ageing may lead to psychological, social and health problems which serve both as risk factors for substance misuse, and which may also be aggravated by substance use.
ix-xjuħija tista’ twassal għal problemi psikoloġiċi, soċjali u ta’ saħħa li jservu bħala fatturi ta’ riskju fir-rigward ta’ l-abbuż mis-sustanzi, u li jistgħu wkoll ikunu aggravati bl-użu ta’ sustanzi.

the eu is addressing the complex social phenomenon of widespread substance use and abuse in the population, and is increasingly focusing on measures to address the harm caused by drugs to individuals and society.
l-ue qed tindirizza dan il-fenomenu soċjali kumpless tat-tixrid tal-użu u tal-abbuż tas-sustanzi fil-popolazzjoni, u qed dejjem tiffoka aktar fuq miżuri biex tkun indirizzata l-ħsara kkawżata mid-droga lill-individwi u lis-soċjetà.

hcv infected patients having a co-occurring substance use disorder (alcohol, cannabis, etc) are at an increased risk of developing psychiatric disorders or exacerbation of already existing psychiatric disorders when treated with alpha interferon.
p azjenti infettati b’hcv li jkollhom ukoll disturb ta’ użu ta’ sustanzi (alkoħol, cannabis, eċċ) ikunu f’riskju akbar li jiżviluppaw disturbi psikjatriċi jew li disturbi psikjatriċi eżistenti minn qabel jaggravaw meta jiġu kkurati b’alpha interferon.

if treatment with alfa interferon is judged necessary in these patients, the presence of psychiatric co-morbidities and the potential for other substance use should be carefully assessed and adequately managed before initiating therapy.
jekk il-kura b’alfa interferon hija meqjusa neċessarja f’dawn il-pazjenti, il-preżenza ta’ ko-morbożitajiet psikjatriċi u l- potenzjal ta’ użu ta’ sustanza oħra għandhom jiġu evalwati b’attenzjoni u mmaniġġjati b’mod xieraq qabel ma tinbeda t-terapija.

overlap of the three dominating diagnostic syndromes in patients with comorbid drug-use disorders
is-sovvrapożizzjoni tat-tlitt sindromi dominanti ta’djanjosi f’pazjenti bi problemi ta’ użu ta’ droga li jsofru minn komorbidità

a european community road safety action programme18 and a council resolution on combating the impact of psychoactive substances use on road accidents19 have been adopted.
programm ta’ azzjoni fuq is-sigurtà fis-sewqan tal-komunità ewropea18 u riżoluzzjoni tal-kunsill fuq il-kombattiment ta’ l-impatt ta’ l-użu ta’ sustanzi psiko-attivi fuq inċidenti tat-traffiku19 kienu adottati.

it lead to the automatic ban of the i.e. ethanol in case of its re-classification as cmr category 1 or 2, despite the substance use in cosmetics is safe.
dan wassal għall-projbizzjoni awtomatika, per eżempju, ta’ l-etanol peress li jagħmel parti mis-sustanzi cmr 1 u 2, anke jekk l-użu tiegħu fil-kosmetika huwa sikur.

7.3 alcohol use disorders are common among older people, particularly among males who are socially isolated, and living alone45.
7.3 il-problemi relatati mal-użu tal-alkoħol huma komuni fost l-anzjani, l-aktar fost l-irġiel li jkunu iżolati soċjalment u jgħixu waħedhom45.